Delisting Determination,The Nasdaq Stock Market, LLC,
May 2, 2019, Synergy Pharmaceuticals, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Synergy Pharmaceuticals, Inc.
(the Company), effective at the opening of the trading
session on May 13, 2019. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5110(b).
The Company was notified of the Staffs determination on
December 12, 2018.  The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
February 4, 2019, granting the Company continued listing
pursuant to an exception that included several milestones
that the Company was required to meet, towards the goal
of regaining compliance with Listing Rule 5110(b).
However, the Company was
unable to meet the exception milestones as required.
On March 6, 2019, the Panel issued a final delisting
determination and notified the Company that trading in the Companys
securities would be suspended on March 8, 2019.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on April 22, 2019.